MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance 1: Double-digit revenue growth and gross margin
MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.
Peer-reviewed publication of ProstACT SELECT 1 results confirm the utility of 68 Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach 2. Consistent with previously reported results 3, the publication highlights TLX591-Tx’s clinical differentiation and
First patient dosed in Phase 3 LUTEON 1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). LUTEON is the first Phase 3 study of a CAIX 2 -targeted radiopharmaceutical therapy in ccRCC. MELBOURNE (Australia) and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE)
First patients dosed in OPTIMAL-e 1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital Sydney. OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA 2 study which recently completed
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help
Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms. Initial focus on TLX101-Px (Pixclara® 1, Floretyrosine F 18) in the U.S. Framework to support potential co-development, validation, and deployment
Telix’s first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates acceptable tolerability across all standard-of-care (SoC) combination cohorts, with no new safety signals. Findings support feasibility of TLX591-Tx in combination with contemporary SoC in